A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Phase 1

Completed

• Conditions: Ovarian Cancer; Epithelial Ovarian Cancer; Bladder Cancer; Fallopian Tube Cancer
• Interventions: Drug: belinostat; Drug: Paclitaxel; Drug: Carboplatin

• Registration Number: NCT00421889
• Lead Sponsor: Valerio Therapeutics

Brief Summary

The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum tolerated dose (MTD) expansion (phase II) in ovarian and bladder cancer patients

The clinical trial is now in the MTD (phase II) portion of the study enrolling bladder cancer patients. Enrollment of ovarian patients is complete.

Detailed Description

MTD Expansion I(Phase II): A total of 18-32 patients with epithelial ovarian, primary peritoneal, fallopian tube or mixed mullerian tumours of ovarian origin, in need of relapse treatment will be enrolled.

MTD Expansion II (phase II): A total of 15 patients with urothelial (transitional cell) carcinoma of the bladder will be enrolled.

Study Timeline

• Study Start: 2005-08
• Study First Submitted: 2007-01-12
• Study First Submitted QC: 2007-01-12
• Study First Posted: 2007-01-15
• Primary Completion: 2009-02
• Study Completion: 2009-02
• Disposition First Submitted: 2012-12-18
• Disposition First Submitted QC: 2012-12-18
• Disposition First Posted: 2012-12-21
• Results First Submitted: 2014-07-01
• Results First Submitted QC: 2014-12-05
• Results First Posted: 2014-12-15
• Status Verified: 2015-07
• Last Update Submitted: 2015-07-07
• Last Update Posted: 2015-07-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

1. Signed consent of an IRB (Institutional Review Board) approved consent form.

2. Patients with histologically confirmed solid carcinomas, for which there is no known curative therapy.

3. Performance status (Eastern Cooperative Oncology Group [ECOG]) ≤ 2.

4. Life expectancy of at least 3 months.

5. Age ≥ 18 years.

6. Acceptable liver, renal and bone marrow function including the following:

   1. Bilirubin ≤ 1.5 times ULN (upper limit of normal).
   2. AST/SGOT ([Aspartate Amino Transferase/Serum glutamic oxaloacetic transaminase]), ALT/SGPT ([Alanine Amino Transferase/Serum glutamic pyruvic transaminase]) and alkaline phosphatase ≤ 3 times ULN (if liver metastases are present, then ≤ 5 x ULN is allowed).
   3. Measured EDTA ([ethylenediaminetetraacetic acid]) renal clearance ≥ 45 mL/min (EU sites). At the US sites calculated creatinine clearance ≥ 45 mL/min using the Jeliffe formula.
   4. Leukocytes > 2.5×109/L, neutrophils > 1.0x109/L, platelets > 100×109/L.
   5. Hemoglobin > 9.0 g/dL or > 5.6 mmol/L.

7. Acceptable coagulation status: PT-INR([prothrombin-International Normalized Ratio])/APTT([Activated Partial Thromboplastin Time]) ≤ 1.5 × ULN or in the therapeutic range if on anticoagulation therapy

8. A negative pregnancy test for women of childbearing potential. For men and women of child-producing potential, the use of effective contraceptive methods during the study is required.

9. Serum potassium within normal range (added in protocol Global version 3.0) Additional Eligibility Criteria at the MTD Expansion only

10. Patients with epithelial ovarian cancer in need of relapse treatment. Changed with protocol Global version 3 to: Patients with epithelial ovarian, primary peritoneal, fallopian tube or mixed mullerian tumors of ovarian origin in need of relapse treatment.

    Or

11. Patients with urothelial (transitional cell) carcinoma of the bladder who have received up to a maximum of 3 previous chemotherapy regimens in the advanced disease setting (neoadjuvant chemotherapy is not included in the total of chemotherapy regimens), applies only for patients enrolled in Part D.

12. At least one uni-dimensional measurable lesion. Lesions must be measured by CT scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST)(Added with protocol Global version 4).

    Eligibility Criteria for the Site Specific Amendment (Part C) - Advanced solid tumors only

13. Patients with refractory solid tumors other than ovarian cancer.

Exclusion Criteria

1. Treatment with investigational agents within the last 4 weeks.

2. Prior anticancer therapy within the last 3 weeks of study dosing including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents. Changed with protocol Global version 1; prior anticancer therapy within the last 3 weeks of study dosing including chemotherapy, radiotherapy, endocrine therapy or immunotherapy.

3. Co-existing active infection or any co-existing medical condition likely to interfere with study procedures, including significant cardiovascular disease (New York Heart Association Class III or IV cardiac disease), myocardial infarction within the past 6 months, unstable angina, congestive heart failure requiring therapy, unstable arrhythmia or a need for anti-arrhythmic therapy, or evidence of ischemia on ECG, marked baseline prolongation of QT/QTc interval, e.g., repeated demonstration of a QTc interval ([corrected QT interval ]) > 500 msec; Long QT Syndrome; the required use of concomitant medication on belinostat infusion days that may cause Torsade de Pointes (see Appendix 1.1, protocol EU version 1.0, Appendix A - Appendix 16.1.1).

4. Altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies.

5. History of a concurrent second malignancy. Changed with Site Specific Amendment (Part D) to: History of a concurrent second malignancy. In patients with urothelial (transitional cell) carcinoma of the bladder an exception is that an incidental finding of localized prostate cancer at the time of radical cystectomy does not preclude inclusion in the study. In such cases a patient will be eligible for inclusion if the Gleason score is ≤6 and the Prostate Specific Antigen (PSA) <10 ng/mL (if the patient would be on hormonal treatment the PSA must be undetectable).Only applied to patients included in this site specific amendment.

6. History of hypersensitivity to either platinum or paclitaxel that is unable to be desensitized (added with protocol Global version 4).

7. More than 3 prior lines of chemotherapy given for metastatic disease (added with protocol Global version 1).

8. Bowel obstruction or impending bowel obstruction.

9. Known HIV positivity.

10. Any Grade 2 or above drug-related neurotoxicity, following recovery.

11. Changed with protocol Global version 1 to: Any existing Grade 2 or above drug related neurotoxicity due to prior treatment with agents causing neurotoxicity.

    Additional exclusion criteria at the MTD expansion only

12. Mixed mullerian tumors of intra-uterine origin, added with protocol Global version 3.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single arm	belinostat	Belinostat: 1000 mg/m2 days 1-5 in a 21 day cycle; IV Paclitaxel: Administered IV 2-3 hours after belinostat infusion on day 3 in a 21-day cycle Carboplatin: Administered IV infusion after paclitaxel on day 3 in a 21-day cycle
Single arm	Paclitaxel	Belinostat: 1000 mg/m2 days 1-5 in a 21 day cycle; IV Paclitaxel: Administered IV 2-3 hours after belinostat infusion on day 3 in a 21-day cycle Carboplatin: Administered IV infusion after paclitaxel on day 3 in a 21-day cycle
Single arm	Carboplatin	Belinostat: 1000 mg/m2 days 1-5 in a 21 day cycle; IV Paclitaxel: Administered IV 2-3 hours after belinostat infusion on day 3 in a 21-day cycle Carboplatin: Administered IV infusion after paclitaxel on day 3 in a 21-day cycle

Primary Outcome Measures

Name	Time	Method
Maximum Tolerable Dose (MTD) Belinostat, Part A,	Cycle 1	To determine the maximum tolerated dose of belinostat (PXD101) in doses up to 1000 mg/m²/day administered in combination with standard doses of carboplatin (AUC of 5) and paclitaxel (175 mg/m2).
Dose Limiting Toxicities (DLT), Part A	Cycle 1	To determine the number of participants experiencing dose limiting toxicities of belinostat (PXD101) in doses up to 1000 mg/m²/day administered in combination with standard doses of carboplatin and paclitaxel or both.

Secondary Outcome Measures

Name	Time	Method
Best Overall Response (CR or PR)	Throughout study until PD (progressive disease) or lost to follow up	Best overall responses were assessed by RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Clinical tumor evaluation will take place after each cycle. Formal radiological evaluation after every 2 cycles. If a response is noted, a follow-up radiographic assessment must be performed 4 weeks (+ 1 week) after the response is noted
To Determine the Pharmacodynamic Effects of Belinostat (in the Combination) on Histone Acetylation in Peripheral Blood Mononuclear Cells (Selected Sites)	Throughout the study
Time to Progression	Throughout study	Time to progression, defined as the interval between the first dates of treatment until the first notation of disease progression. RECIST criteria
Time to Response	Throughout study	Time to response (RECIST) was assessed as the interval between the first dates of treatment until the first notation of response.
Duration of Response	Throughout study	Defined as interval from the time criteria for CR or PR are met, until the first date that recurrent or progressive disease is objectively documented.
Belinostat Cmax	Cycle 1 day 1: Pre-Infusion, 0 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 3 h 15 min, 3 h 30 min, 4 h, 5 h, 6 h, 6 h 15 min, 6 h 30 min, 7h, 8h, 9h, 24h
Belinostat Mean t½	Cycle 1 Day 1: Cycle 1 day 1: Pre-Infusion, 0 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 3 h 15 min, 3 h 30 min, 4 h, 5 h, 6 h, 6 h 15 min, 6 h 30 min, 7h, 8h, 9h, 24h
Belinostat AUC (0-infinity)	Cycle 1 Day 1: Cycle 1 day 1: Pre-Infusion, 0 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 3 h 15 min, 3 h 30 min, 4 h, 5 h, 6 h, 6 h 15 min, 6 h 30 min, 7h, 8h, 9h, 24h

Trial Locations

Locations (11)

Greater Baltimore Medical Center; 🇺🇸 Baltimore, Maryland, United States

Hematology & Oncology Specialists, LLC; 🇺🇸 Metairie, Louisiana, United States

The Royal Marsden NHS Trust; 🇬🇧 Surrey, United Kingdom

Research Facility, Herlev University Hospital; 🇩🇰 Herlev, Denmark

Massachusetts General Hospital Cancer Center; 🇺🇸 Boston, Massachusetts, United States

The Beatson West of Scotland Cancer Centre; 🇬🇧 Glasgow, United Kingdom

Research Facility; 🇺🇸 Orlando, Florida, United States

The Finsen Center, Rigshospitalet; 🇩🇰 Copenhagen, Denmark

Women & Infants Hospital of Rhode Island; 🇺🇸 Providence, Rhode Island, United States

Gynecologic Oncology Associates; 🇺🇸 Newport Beach, California, United States

Hematology and Oncology Specialists, LLC; 🇺🇸 Covington, Louisiana, United States